How do pharma and biotech companies ensure GDP-compliant distribution of their medicinal products across the entire supply chain?

Good Distribution Practice under the EU Guidelines 2013/C 343/01 does not begin in the warehouse, but at the handover points. The sequence is decisive: only once the quality system with a responsible person, self-inspection and risk management is in place does it make sense to build the SOPs for incoming goods, storage and shipping. Only then are the distribution partners qualified and audited, because a non-GDP-compliant intermediary devalues every internal procedure. And only once storage and partners are settled does the validation of the transport lane through a lane study under worst-case conditions close the chain. Anyone who reverses this sequence and starts with transport validates lanes whose handover responsibility has not yet even been clarified.

The bottleneck is almost always end-to-end traceability. It does not hinge on the well-documented in-house warehouse, but on the weakest handover in the chain, for example an unqualified lane, an unaudited partner or an unregulated quality agreement. In a recall this becomes apparent at once, because affected batches must be identified and isolated across all stages, and the recall must be capable of being initiated promptly at any time. Our gap analysis therefore starts at the interfaces first, before capacity is committed to audits and lane studies, so that the effort goes where the chain would actually break.